NRSN

NeuroSense Therapeutics Ltd. NRSN

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-11.13M

Quarter to Dec 31

Free cash flow

$-7.68M

Quarter to Dec 31

Top Institutional Holders

as of Q2 2026
$296.1K total
UBS Group AG
$78.3K+118.5%
Independent Advisor Alliance
$72.0K+100.0%
Yorkville Advisors Global, LP
$56.2K0.0%
COMMONWEALTH EQUITY SERVICES, LLC
$16.4K0.0%
PNC FINANCIAL SERVICES GROUP, INC.
$15.2K0.0%
Pathstone Holdings, LLC
$11.9K0.0%
GEODE CAPITAL MANAGEMENT, LLC
$11.4K0.0%
XTX Topco Ltd
$8.3KNew
Creative Planning
$8.2K-4.2%
HRT FINANCIAL LP
$7.0KNew
Empery Asset Management, LP
$6.3K0.0%
Clear Street Group Inc.
$4.0K-0.5%
JONES FINANCIAL COMPANIES LLLP
$7570.0%
SBI Securities Co., Ltd.
$184-3.8%
See all 14 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

FY 2025
EDGAR

EPS (Diluted)

FY 2025
EDGAR

Free Cash Flow

FY 2025
EDGAR

Loading ratio trend…

NRSN insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About NeuroSense Therapeutics Ltd. (NRSN): stock profile, AI score and financials

NeuroSense Therapeutics Ltd. (NRSN) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. NRSN is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (FY 2025), NeuroSense Therapeutics Ltd. reports net income of $-11.1M, free cash flow of $-7.7M. Top institutional holders of NRSN by reported 13-F value include UBS Group AG, Independent Advisor Alliance, Yorkville Advisors Global, based on the most recent SEC filings. NRSN trades on the Nasdaq exchange and files with the SEC under CIK 1875091. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NRSN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for NeuroSense Therapeutics Ltd. directly from SEC EDGAR.

SEC EDGAR: CIK 1875091 →